Maxim Upgrades Gilead Sciences to 'Buy' Gilead Sciences, Inc. 's (NASDAQ:GILD) recent upgrade to 'Buy' by Maxim analyst Michael Okunewitch has sent shockwaves through the biopharmaceutical industry.
The upgrade comes with a price target of $165, representing an upside of over 25% from current levels.
The upgrade is primarily driven by Gilead's core business growth, which Maxim expects to reach 5 6% in coming years.